Home
About
Overview
Sharing Data
ORCID
Help
History (5)
Allosteric inhibition of a stem cell RNA-binding protein by an intermediary metabolite.
Discontinuation of rivaroxaban: filling in the gaps.
Novel methodology for the evaluation of symptoms reported by patients with newly diagnosed atrial fibrillation: Application of natural language processing to electronic medical records data.
Protective effect of LNA-anti-miR-132 therapy on liver fibrosis in mice.
Vocabulary, Controlled
See All 5 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Discontinuation of rivaroxaban: filling in the gaps.
Reynolds MR. Discontinuation of rivaroxaban: filling in the gaps. J Am Coll Cardiol. 2013 Feb 12; 61(6):659-60.
View in:
PubMed
subject areas
Atrial Fibrillation
Blood Coagulation
Female
Humans
Male
Morpholines
Risk Assessment
Rivaroxaban
Stroke
Thiophenes
Thromboembolism
Warfarin
authors with profiles
Matthew R Reynolds MD, MSc